Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition READOUT: Deputy Undersecretary Lee visits Colombia, engages with new Petro administration leaders on labor compliance under trade agreement

Issued: London UK

Following media coverage this weekend, GSK has issued the following statement:

“The issues relating to our China business are very difficult and complicated.

“The investigation by the Chinese authorities remains ongoing and we are co-operating fully with this investigation. Out of respect for the process we cannot comment on it at this time.

“We have zero tolerance for any kind of corruption in our business and we have many policies, procedures, controls in place to monitor this and we take action against any breaches.

“As we have said previously, the allegations that have been raised are deeply concerning to us. We have committed significant resources to find out what happened in China, including an independent legal review. We also continue to make fundamental changes to our business in China.

“We are learning lessons from this situation and we are determined to take all actions necessary as a result.”

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

Source link